论文部分内容阅读
目的:探究食管癌患者纤维蛋白原(FIB)与D-二聚体(D-D)检测的临床意义。方法:回顾性选取2015年6月-2016年6月收治的35例食管癌患者作为研究组,并将同期行健康体检正常者30例作为对照组,患者均行FIB及D-D检测,观察两组FIB与D-D、研究组不同时期FIB与D-D阳性率及含量。结果:研究组FIB(4.17±6.55)g/L与D-D(0.63±0.41)mg/L显著高于对照组(2.72±4.63)g/L和(0.31±0.23)mg/L(P<0.05);研究组Ⅰ期FIB和D-D阳性率14.28%和28.57%显著低于Ⅱ期26.66%和73.33%以及Ⅲ期61.53%和92.30%,Ⅲ期检出阳性率61.53%和92.30%最高,且同一时期D-D阳性率28.57%、73.33%及92.30%高于FIB14.28%、26.66%及61.53%(P<0.05);研究组FIB及D-D含量Ⅲ期(4.21±6.26)g/L与(0.79±0.53)mg/L高于Ⅰ期(3.19±4.71)g/L、(0.56±0.32)mg/L以及Ⅱ期(3.82±4.78)g/L、(0.61±0.58)mg/L,且呈逐步上升趋势(P<0.05)。结论:食管癌患者血浆中纤维蛋白原及D-二聚体水平高于健康人群,根据其含量能够帮助病情诊断和及早治疗,达到良好预后。
Objective: To investigate the clinical significance of detecting fibrinogen (FIB) and D-dimer (D-D) in patients with esophageal cancer. Methods: Thirty-five patients with esophageal cancer who were admitted to our hospital from June 2015 to June 2016 were retrospectively selected. Thirty patients with normal physical examination in the same period were selected as control group. FIB and DD were detected in both groups. FIB and DD, the study group FIB and DD positive rate and content in different periods. Results: The FIB (4.17 ± 6.55) g / L and DD (0.63 ± 0.41) mg / L in the study group were significantly higher than those in the control group (2.72 ± 4.63 g / L and 0.31 ± 0.23 mg / ; The positive rates of FIB and DD in study group I were 14.28% and 28.57% respectively, significantly lower than those in stage II 26.66% and 73.33%, stage III 61.53% and stage 92.30%, stage III 61.53% and stage 92.30% The positive rates of DD in the study group were 28.57%, 73.33% and 92.30% higher than those of FIB14.28%, 26.66% and 61.53% respectively (P <0.05) ) was higher than that of stage Ⅰ (3.19 ± 4.71) g / L, (0.56 ± 0.32) mg / L and Ⅱ phase (3.82 ± 4.78) g / L and (0.61 ± 0.58) mg / L respectively Trend (P <0.05). Conclusion: The plasma levels of fibrinogen and D-dimer in patients with esophageal cancer are higher than those in healthy people. According to their content, they can help to diagnose and treat the disease well and reach a good prognosis.